Evaluation of the clinical significance of focal adhesion kinase and src expression in human pancreatic ductal adenocarcinoma

Pancreas

Volumn 39, Issue 6, 2010, Pages 930-936

  Chatzizacharias, Nikolaos A ^a,b   Giaginis, Constantinos ^a   Zizi Serbetzoglou, Diamanto ^c   Kouraklis, Gregory P ^d   Karatzas, Gabriel ^e   Theocharis, Stamatios E ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Tzaneio General Hospital   (Greece)

^d Second Department of Propedeutic Surgery   (South Africa)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

FAK; pancreatic cancer; Src

Indexed keywords

FOCAL ADHESION KINASE; PROTEIN TYROSINE PHOSPHATASE SHP;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SRC HOMOLOGY DOMAIN; SURVIVAL; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS PP60(C-SRC);

EID: 77955230400     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181d7abcc     Document Type: Article

References (38)

1. Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer. 2002;26:176-275.
2. Pancreatic Cancer Treatment. Bethesda, MD: National Cancer Institute; 1996. Updated January 7, 2009, [online database].
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
4. Moore MJ GD, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCICCTG]. J Clin Oncol. 2005;1 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement).
5. Cunningham DCI, Stocken D, et al. GEM-CAP: PHASE III radnomised comparison of gemcitabine with gemcitabine plus capecitabine in patients with advanced pancreas cancer. ECCO 2005, #PS11.
6. Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992;358:690-692.
7. Schaller MD, Borgman CA, Cobb BS, et al. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A. 1992;89:5192-5196.
8. Hanks SK, Calalb MB, Harper MC, et al. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A. 1992;89:8487-8491.
9. Lipfert L, Haimovich B, Schaller MD, et al. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol. 1992;119:905-912.
10. Zachary I, Sinnett-Smith J, Rozengurt E. Bombesin, vasopressin, and endothelin stimulation of tyrosine phosphorylation in Swiss 3T3 cells. Identification of a novel tyrosine kinase as a major substrate. J Biol Chem. 1992;267:19031-19034.
11. Zachary I. Focal adhesion kinase. Int J Biochem Cell Biol. 1997;29:929-934.
12. Schaller MD, Parsons JT. Focal adhesion kinase and associated proteins. Curr Opin Cell Biol. 1994;6:705-710.
13. Salasznyk RM, Klees RF, Williams WA, et al. Focal adhesion kinase signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells. Exp Cell Res. 2007;313:22-37.
14. Cary LA, Guan JL. Focal adhesion kinase in integrin-mediated signaling. Front Biosci. 1999;4:D102-D113.
15. Xing Z, Chen HC, Nowlen JK, et al. Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell. 1994;5:413-421.
16. Rahimi N, Hung W, Tremblay E, et al. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem. 1998;273:33714-33721.
17. Hauck CR, Hunter T, Schlaepfer DD. The v-Src SH3 domain facilitates a cell adhesion-independent association with focal adhesion kinase. J Biol Chem. 2001;276:17653-17662.
18. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002;1602:114-130.
19. Schlaepfer DD, Hauck CR, Stieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71:435-478.
20. Cox BD, Natarajan M, Stettner MR, et al. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006;99:35-52.
21. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Clinical significance of FAK expression in human neoplasia. Histology and Histopathology. Histol Histopathol. 2008;23:629-650.
22. Summy JM, Gallick GE. Src Family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358.
23. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Focal adhesion kinase: a promising target for anticancer therapy. Expert Opin Ther Targets. 2007;11:1315-1328.
24. Trevino JG, Summy JM, Gallick GE. Src inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem. 2006;6:681-687.
25. Siu LL, Burris HA, Mileshkin L, et al. Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with advanced solid tumors. J Clin Oncol. 2007;25:3527 2007 ASCO Annual Meeting Proceedings.
26. A Study of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies (B0761001). [Clinical Trials Web site]. November 5, 2008. Updated July 1, 2009. Available at: http://clinicaltrials.gov/ct2/ show/NCT00787033. Accessed July 1, 2009.
27. Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZDO53O, a Selective Src Kinase Inhibitor, in Patients With Recurrent Osteosarcoma Localized to the Lung. [Clinical Trials Web site]. June 17, 2009. Updated June 26, 2009. Available at: http://clinicaltrials.gov/ct2/ show/ NCT00923286?term=src&rank=1. Accessed July 1, 2009.
28. Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC (TOP0801). [Clinical Trials Web site]. November 6, 2008. Updated February 25, 2009. Available at: http://clinicaltrials.gov/ ct2/show/NCT00787267?term= src&rank=8. Accessed July 1, 2009.
29. A Phase I/II Study of Dasatinib and Dacarbazine. [Clinical Trials Web site]. January 8, 2008. Updated April 20, 2009. Available at: http://clinicaltrials.gov/ct2/show/ NCT00597038?term=src+inhibitor&rank=3. Accessed July 1, 2009.
30. Phase I Dasatinib/Erlotinib in Recurrent NSCLC. [Clinical Trials Web site]. March 5, 2007. Updated January 30, 2009. Available at: http://clinicaltrials.gov/ct2/show/ NCT00444015?term=src+inhibitor&rank=5. Accessed July 1, 2009.
31. Furuyama K, Doi R, Mori T, et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg. 2006;30:219-226.
32. Lutz M, Eber IBC, Flossmann-Kast BBM, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Com. 1998;243:503-508.
33. Kloeppel G, Solcia E, Longnecker DS, et al. International histological classifications for tumours. In: World Health Organization, ed. Histological Typing for Tumours of the Exocrine Pancreas. 2nd ed. Berlin: Spinger; 1996.
34. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 5th ed. New York: Wiley-Liss; 1997.
35. Exocrine pancreas. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:157-164.
36. Giaginis C, Davides D, Zarros A, et al. Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma. Dig Dis Sci. 2008;53:1728-1734.
37. Ischenko I, Guba M, Yezhelyev M, et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis. 2007;10:167-182.
38. Ischenko I, Camaj P, Seeliger H, et al. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signalling. Oncogene. 2008;27:7212-7222.